AstraZeneca (AZ) has signed a global oncology collaboration with Merck & Co. to co-develop and co-commercialise AZ’s Lynparza™ (olaparib) for multiple cancer types in a deal worth up to US$8.5 B. The agreement was announced the same day AZ released results that its crucial MYSTIC trial, evaluating Imfinzi™ (durvalumab) as a monotherapy and in combination with tremelimumab, had failed to reach its primary end point.